NASDAQ · FOSLHealthcareMedical Instruments & Devices

Fossil Group financials

$6.16+2.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Jan 3
FY24
Dec 28
FY23
Dec 30
FY22
Dec 31
FY21
Jan 1
FY20
Jan 2
FY19
Dec 28
FY18
Dec 29
FY17
Dec 30
FY16
Dec 31
Revenue$1.00B$1.14B$1.41B$1.68B$1.87B$1.61B$2.22B$2.54B$2.79B$3.04B
Gross profit$563.1M$597.2M$679.6M$830.7M$966.4M$770.4M$1.10B$1.34B$1.36B$1.58B
Gross margin56.1%52.2%48.1%49.4%51.7%47.7%49.6%52.7%48.7%51.9%
Operating income-$19.1M-$103.9M-$143.0M-$1.5M$92.6M-$135.3M-$28.4M$62.7M-$424.3M$127.1M
Net income-$78.3M-$102.7M-$157.1M-$44.2M$25.4M-$96.1M-$52.4M-$3.5M-$478.2M$78.9M
Net margin−7.8%−9.0%−11.1%−2.6%1.4%−6.0%−2.4%−0.1%−17.2%2.6%
Diluted EPS$-1.45$-1.94$-3.00$-0.85$0.48$-1.88$-1.04$-0.07$-9.87$1.63
EBITDA$36.1M-$25.6M-$78.5M$30.3M$153.4M-$21.6M$81.3M$183.1M$112.0M$249.5M
Operating cash flow-$57.9M$46.7M-$59.5M-$110.9M$50.0M$101.2M-$14.2M$248.1M$179.5M$210.1M
Free cash flow-$60.5M$39.9M-$68.0M-$124.1M$39.7M$92.5M-$35.1M$230.2M$154.0M$144.5M
Diluted shares54.1M53.0M52.3M51.8M52.8M51.1M50.2M49.2M48.5M48.3M

Balance sheet

Period endJan 3Dec 28Dec 30Dec 31Jan 1Jan 2
Cash & equivalents$95.8M$123.6M$117.2M$198.7M$250.8M$316.0M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$177.8M$164.8M$207.5M$216.5M$141.9M$227.4M
Total assets$689.3M$763.6M$978.0M$1.24B$1.37B$1.48B
Total liabilities$602.5M$626.8M$726.3M$835.1M$903.4M$1.04B
Shareholders' equity$86.8M$136.7M$251.7M$403.0M$465.4M$440.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology